Serum thioredoxin reductase is highly increased in mice with hepatocellular carcinoma and its activity is restrained by several mechanisms.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Free Radical Biology & Medicine

• Publication date

  2016-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.freeradbiomed.2016.08.028PMID 27581528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity

  2017cited by this paper
• Thioredoxin reductase: A novel, independent prognostic marker in patients with hepatocellular carcinoma

  2015cited by this paper
• Disulfide bond generation in mammalian blood serum: detection and purification of quiescin-sulfhydryl oxidase.

  2014cited by this paper
• Serum thioredoxin reductase levels increase in response to chemically induced acute liver injury.

  2014influential reference
• The thioredoxin antioxidant system.

  2014cited by this paper
• Why Is Mammalian Thioredoxin Reductase 1 So Dependent upon the Use of Selenium?

  2014cited by this paper
• An inhibitory antibody blocks the first step in the dithiol/disulfide relay mechanism of the enzyme QSOX1.

  2013influential reference
• Inhibition of glutathione synthesis eliminates the adaptive response of ascitic hepatoma 22 cells to nedaplatin that targets thioredoxin reductase.

  2012cited by this paper
• Small molecule inhibitors of mammalian thioredoxin reductase.

  2012cited by this paper
• Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay.

  2011cited by this paper
• The Selenium-independent Inherent Pro-oxidant NADPH Oxidase Activity of Mammalian Thioredoxin Reductase and Its Selenium-dependent Direct Peroxidase Activities*

  2010cited by this paper
• Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury.

  2010cited by this paper
• Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin.

  2010cited by this paper
• Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer

  2010cited by this paper
• Inhibition of Both Thioredoxin Reductase and Glutathione Reductase may Contribute to the Anticancer Mechanism of TH-302

  2010influential reference
• Focus on mammalian thioredoxin reductases--important selenoproteins with versatile functions.

  2009cited by this paper
• Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria.

  2009cited by this paper
• Crystal Structure and Catalysis of the Selenoprotein Thioredoxin Reductase 1*

  2009cited by this paper
• Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy.

  2008cited by this paper
• Cell Death by SecTRAPs: Thioredoxin Reductase as a Prooxidant Killer of Cells

  2008cited by this paper
• Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.

  2007cited by this paper
• Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity.

  2007cited by this paper
• From Selenium to Selenoproteins: Synthesis, Identity, and Their Role in Human Health

  2007cited by this paper
• Thioredoxin reductase as a novel molecular target for cancer therapy.

  2006cited by this paper
• Redox Regulation of Human Thioredoxin Network

  2006cited by this paper
• Thioredoxin Reductase 1 Deficiency Reverses Tumor Phenotype and Tumorigenicity of Lung Carcinoma Cells*

  2006cited by this paper
• Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo.

  2006cited by this paper
• Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.

  2005cited by this paper
• Thioredoxin secreted upon ultraviolet A irradiation modulates activities of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in human dermal fibroblasts.

  2004cited by this paper
• The thioredoxin-thioredoxin reductase system: over-expression in human cancer.

  2003cited by this paper
• Interactions of Quinones with Thioredoxin Reductase

  2003cited by this paper
• Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.

  2001cited by this paper
• Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma.

  2001cited by this paper
• Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion.

  2001cited by this paper
• Physiological functions of thioredoxin and thioredoxin reductase.

  2000cited by this paper
• Essential Role of Selenium in the Catalytic Activities of Mammalian Thioredoxin Reductase Revealed by Characterization of Recombinant Enzymes with Selenocysteine Mutations*

  2000cited by this paper
• Thioredoxin reductase.

  2000cited by this paper
• Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma.

  2000cited by this paper
• The novel oxidoreductase KDRF (KM-102-derived reductase-like factor) is identical with human thioredoxin reductase.

  1997cited by this paper
• Cloning and Characterization of a Novel Oxidoreductase KDRF from a Human Bone Marrow-derived Stromal Cell Line KM-102*

  1997cited by this paper
• High-performance liquid chromatographic assays for protoporphyrinogen oxidase and ferrochelatase in human leucocytes.

  1991cited by this paper
• Pathophysiology of cutaneous lesions in porphyrias.

  1989cited by this paper
• Pathophysiology of cutaneous lesions in porphyrias.

  1989cited by this paper
• High-performance liquid chromatographic determination of protoporphyrin and zinc protoporphyrin in blood.

  1980cited by this paper
• Erythropoietic Protoporphyria

  1973cited by this paper

• (−)-Epigallocatechin-3-Gallate and Quercetin Inhibit Quiescin Sulfhydryl Oxidase 1 Secretion from Hepatocellular Carcinoma Cells

  2025cites this paper
• Serum dithiothreitol-oxidizing capacity (DOC) is a promising biomarker for excluding significant liver fibrosis: a proof-of-concept study

  2024cites this paper
• The C-terminal selenenylsulfide of extracellular/non-reduced thioredoxin reductase endows this protein with selectivity to small-molecule electrophilic reagents under oxidative conditions

  2024cites this paper
• A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy against Hepatocarcinoma.

  2023cites this paper
• A glycyrrhetinic acid-iridium(III) conjugate as a theranostic NIR probe for hepatocellular carcinoma with mitochondrial-targeting ability.

  2023cites this paper
• Thioredoxin Reductase and Organometallic Complexes: A Pivotal System to Tackle Multidrug Resistant Tumors?

  2023cites this paper
• Tumor-Targeting NHC-Au(I) Complex Induces Immunogenic Cell Death in Hepatocellular Carcinoma.

  2023cites this paper
• Thioredoxin Reductase Inhibition for Cancer Therapy.

  2021cites this paper
• Evaluation of dithiothreitol-oxidizing capacity (DOC) as a serum biomarker for chronic hepatitis B in patients exhibiting normal alanine aminotransferase levels: a pilot study towards better monitoring of disease

  2021cites this paper
• Perspectives of TrxR1-based cancer therapies

  2020cites this paper
• Halo and Pseudohalo Gold(I)-NHC Complexes Derived from 4,5-Diarylimidazoles with Excellent in Vitro and in Vivo Anticancer Activity Against HCC.

  2020cites this paper
• Pharmacological mechanisms of the anticancer action of sodium selenite against peritoneal cancer in mice.

  2019cites this paper
• Selenium nanoparticles act as an intestinal p53 inhibitor mitigating chemotherapy-induced diarrhea in mice.

  2019cites this paper
• Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells

  2019cites this paper
• Selenium nanoparticles are more efficient than sodium selenite in producing reactive oxygen species and hyper‐accumulation of selenium nanoparticles in cancer cells generates potent therapeutic effects

  2018cites this paper
• Quiescin sulfhydryl oxidase 1 (QSOX1) glycosite mutation perturbs secretion but not Golgi localization

  2018cites this paper
• NADPH-dependent and -independent disulfide reductase systems.

  2018cites this paper
• Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity

  2017cites this paper